Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: A potential biomarker for radiographic progression

Clinical Rheumatology

Volumn 32, Issue 11, 2013, Pages 1661-1666

  Nishina, Naoshi ^a   Kaneko, Yuko ^a   Kameda, Hideto ^a   Kuwana, Masataka ^a   Takeuchi, Tsutomu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Interleukin 6; Methotrexate; Rheumatoid arthritis; Tumor necrosis factor alpha

Indexed keywords

BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; METHOTREXATE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DAS28; DISEASE ACTIVITY SCORE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-6; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886296315     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2309-0     Document Type: Article

References (15)

1. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, Bombardier C, Carmona L, van der Heijde D, Bijlsma JW, Boumpas DT, Canhao H, Edwards CJ, Hamuryudan V, Kvien TK, Leeb BF, Martin-Mola EM, Mielants H, Muller-Ladner U, Murphy G, Ostergaard M, Pereira IA, Ramos-Remus C, Valentini G, Zochling J, Dougados M (2009) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative. Ann Rheum Dis 68(7):1086-1093. doi: 10.1136/ard.2008.094474
2. Smolen JS, Aletaha D, Redlich K (2012) The pathogenesis of rheumatoid arthritis: new insights from old clinical data? Nat Rev Rheumatol 8(4):235-243. doi: 10.1038/nrrheum.2012.23
3. Wessels JA, Huizinga TW, Guchelaar HJ (2008) Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 47(3):249-255. doi: 10.1093/rheumatology/kem279 (Pubitemid 351267187)
4. Kraan MC, Smeets TJ, van Loon MJ, Breedveld FC, Dijkmans BA, Tak PP (2004) Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis 63(9):1056-1061. doi: 10.1136/ard.2003.014738 (Pubitemid 39120354)
5. McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205-2219. doi: 10.1056/NEJMra1004965
6. de Lathouder S, Gerards AH, Dijkmans BA, Aarden LA (2004) Two inhibitors of DNA-synthesis lead to inhibition of cytokine production via a different mechanism. Nucleosides Nucleotides Nucleic Acids 23(8-9):1089-1100. doi: 10.1081/NCN-200027365 (Pubitemid 39625874)
7. Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA (2003) Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 42(10):1189-1196. doi: 10.1093/rheumatology/keg323 (Pubitemid 37258482)
8. van der Heijde D (2000) How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 27(1):261-263 (Pubitemid 30058662)
9. Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, Koike T (2011) Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 70(7):1208-1215. doi: 10.1136/ard.2011.153023
10. Bruynesteyn K, Van Der Heijde D, Boers M, Saudan A, Peloso P, Paulus H, Houben H, Griffiths B, Edmonds J, Bresnihan B, Boonen A, Van Der Linden S (2002) Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence. J Rheumatol 29(11):2306-2312 (Pubitemid 35266020)
11. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964-975. doi: 10.1136/ard.2009.126532
12. Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, Schett G, Amital H, Navarro-Sarabia F, Hou A, Bernasconi C, Huizinga T (2012) Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. doi: 10.1136/annrheumdis-2011-201282
13. Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, Sato E, Saito K, Kaneko Y, Fukuyo S, Kurasawa T, Hanami K, Kameda H, Yamanaka H (2011) Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-reaction 52-week study. Rheumatology (Oxford) 50(10):1908-1915. doi: 10.1093/rheumatology/ker221
14. McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7(6):429-442. doi: 10.1038/nri2094 (Pubitemid 46834849)
15. Visser K, van der Heijde D (2009) Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 68(7):1094-1099. doi: 10.1136/ard.2008.092668 Technology